Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.02 Per Share

Wall Street brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to post earnings per share (EPS) of ($0.02) for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.01 and the lowest estimate coming in at ($0.06). Vanda Pharmaceuticals posted earnings per share of ($0.04) during the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The company is scheduled to announce its next quarterly earnings results on Wednesday, February 13th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year earnings of $0.22 per share for the current financial year, with EPS estimates ranging from $0.18 to $0.28. For the next financial year, analysts expect that the company will post earnings of $0.66 per share, with EPS estimates ranging from $0.23 to $0.99. Zacks’ EPS calculations are a mean average based on a survey of analysts that follow Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. The business had revenue of $49.13 million during the quarter, compared to analysts’ expectations of $49.44 million. During the same quarter in the prior year, the company posted ($0.03) EPS. The firm’s revenue for the quarter was up 18.9% compared to the same quarter last year.

Several equities research analysts have recently commented on VNDA shares. TheStreet raised shares of Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, October 26th. Oppenheimer set a $27.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Seaport Global Securities reaffirmed a “buy” rating and issued a $26.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, August 2nd. Stifel Nicolaus started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, September 13th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Citigroup raised their target price on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, October 16th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $27.43.

Large investors have recently bought and sold shares of the company. Trexquant Investment LP purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $212,000. Hartford Investment Management Co. purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $214,000. NumerixS Investment Technologies Inc lifted its position in Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 5,700 shares during the period. Xact Kapitalforvaltning AB purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $240,000. Finally, Meeder Asset Management Inc. lifted its position in Vanda Pharmaceuticals by 164.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 7,102 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:VNDA traded up $3.01 on Thursday, hitting $23.46. The company had a trading volume of 1,937,092 shares, compared to its average volume of 689,271. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $25.07. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -67.03 and a beta of 1.06.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: Short Selling Stocks and Day Traders

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply